1910 Genetics

1910 Genetics is a biotechnology company that integrates AI, computation, and biological automation to accelerate the design of small molecule and protein therapeutics. The company has developed two discovery engines, ELVIS and PAULI, that use computational approaches to identify and optimize drug candidates for treating pain, aging-related diseases, and other conditions. 1910 Genetics combines artificial intelligence with automated laboratory systems to dramatically reduce the time and cost of drug discovery, enabling the exploration of chemical space that is inaccessible to traditional methods. The company platform integrates computational drug design with high-throughput experimental validation, creating a closed-loop system where AI predictions are continuously refined by experimental results. Founded in 2018 and headquartered in Cambridge, Massachusetts, 1910 Genetics has raised approximately $29.8 million in Series A funding from investors including Y Combinator, FoundersX Ventures, Scientia Ventures, M12, Playground Global, Accenture, and the NIH.

Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics > Lead Discovery > AI Based